ESR1 and cancer: Conversely, in both clinical phenotypes with significant percentages of genomically claudin-low cancers, the ER-positive/HER2-negative/low proliferation phenotype and the ER-negative/HER2-negative phenotype, claudin-low cancers differ in several characteristics and molecular attributes compared with the dominant cancers in the phenotype, luminal A and basal-like, respectively.